Vaccines Webinars

This webinar will explore two different approaches to Correlates of Protection in vaccine development. Statistical models providing a quantitative framework for identification and validation of potential CoPs, and mechanistic models aiming to understand the biological mechanisms driving immune responses and protection. By integrating these two approaches, researchers can gain better insights into the immunological factors associated with vaccine efficacy and infection protection. This webinar will include talks from two renowned speakers who will discuss the principles, applications, and challenges of both statistical and mechanistic models, contributing to a better understanding of CoPs and optimizing vaccine clinical trial design. Who is this event intended for? Statisticians, Mathematicians, Modelers, working in vaccine development. What is the benefit of attending? Attending this seminar on Correlates of Protection (CoPs) in vaccine development offers several benefits. Firstly, participants will gain insights into statistical models used to identify and validate CoPs, providing them with quantitative tools for assessing vaccine efficacy. Secondly, they will learn about mechanistic models that elucidate the underlying biological mechanisms driving immune responses, enhancing their understanding of vaccine-induced protection.

DescriptionDr. Marc Brisson is full professor at Laval University where he leads the Research Group in Mathematical Modeling and Health Economics of Infectious Diseases. His research aims at developing mathematical models that predict the effectiveness and cost-effectiveness of interventions against infectious diseases to help policy decision-making. His current research mainly focuses on cervical cancers and COVID-19. Dr. Brisson has produced over 110 peer reviewed journal articles (including high impact journals such as The Lancet and The Lancet Family, JNCI, BMJ, and Annals of Internal Medicine), and made over 115 presentations at conferences, external seminars and workshops (over 60 as invited speaker). He has consulted for the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), the Canadian Partnership Against Cancer (CPAC), the Public Health Agency of Canada (PHAC) and the Canadian Immunization Committee (CIC). He has a BSc in Actuarial Science (1992-1996), a certificate in Statistics (1996) and an MSc in Epidemiology (1996-2001) from Laval University in Quebec City, and a PhD in Health Economics (1999-2004) from City University in London, England.

Zoster Vaccine for patients with renal disease Target Audience Technicians and Health Assistants Laboratories and Medical Technology Family Medicine Internal Medicine General Practice Clinical Pathology Allergy and Immumology Public Health, Nephrology Endocrinology, Renal transplant Nursing and Midwifery Pharmacists and Pharmacy Technicians

Empirical and theoretical evidence shows that mass dog vaccination interrupts the transmission cycle and if sustained can eliminate dog-mediated rabies. But constraints and barriers can prevent vaccination campaigns from reaching target or sufficient coverage of the dog population. There are resources and tools available to help overcome many of these constraints and barriers, but are they reaching the right audiences? And are any constraints or barriers left unaddressed? Join this webinar to learn more about addressing these barriers in order to scale up dog vaccination campaigns to effectively prevent and control rabies.

The development of effective vaccines is among the greatest advancements in public health to combat infectious diseases. It is a complex multi-year and multi-stakeholder process that requires well-designed strategy, partnership, and preparedness among the clinical, operational, and laboratory experts. In this webinar, hear from experts on the importance of having an integrated approach among the clinical and laboratory teams well before the protocol development and how robust laboratory and IT capabilities along with innovative automation help improve the efficiency of vaccine development.

Understand diabetes and the connection to Covid autoimmunity as it relates to both infection and vaccination.

Where is the current science on explaining Covid long haul disease? What options could be on the horizon?

Discover an informative webinar delving into the evolution of vaccine platform technologies to the current era of mRNA vaccines, with a discussion on the unique challenges they face in their advancements to clinical trials. The experts, Dr. Narendra Deshmukh and Dr. Kedar Purnapatre will discuss some of the many challenges facing the vaccine development industry today in the demonstration of product quality, immunogenicity and safety. They will share their experience working with various vaccine and adjuvant types emphasizing the importance of appropriately designed experiments, biomarker selection, and choice of appropriate bioassays and bioanalytical tools. Join this webinar to gain insights into the challenges and innovations in mRNA vaccines in clinical trials.